Next Generation CAR & T Cell Therapies is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


John Tomitshen
Associate Director of Manufacturing, CMC at Legend Biotech Co., USA


John Tomtishen is currently employed by Legend Biotech in Piscataway, NJ. At Legend, John has oversight over Legend Biotech’s U.S. Manufacturing and Technical Operation teams and is responsible for developing a robust global CMC strategy to manufacture cell and gene therapy products, including LCAR-B38M/JNJ-68284528 in collaboration with Janssen Pharmaceuticals. Prior to joining Legend, John was employed by Novartis Pharmaceuticals within Cell and Gene Technical Development & Manufacturing in Morris Plains, NJ where he worked in a variety of CMC roles overseeing cell and gene therapy products from late stage clinical development through commercial lifecycle management. During his time at Novartis, John had an integral role in the filing and approval of the first CAR-T BLA (Kymriah™- tisagenlecleucel) for the treatment of pALL in addition to a supplemental BLA for the treatment of DLBCL.

John Tomitshen's Network

Agenda Sessions

  • Avoiding CMC Pitfalls: Roadmap for Cell Therapy Commercialization

    , 3:45pm